Archive for the ‘Health Care’ Category

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma

ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]

August 24, 2011  Tags: , , ,   Posted in: Chief Medical Officer, Chief executive officer, Clinical Research, Clinical trial, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]

July 7, 2011  Tags: , , , , ,   Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Health Care, US Food and Drug Administration., fuad el-hibri  No Comments

Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]

January 5, 2011  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri  No Comments

Emergent BioSolutions to Acquire Trubion Pharmaceuticals

Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income

ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]

August 19, 2010  Tags: , , , , , , ,   Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri  No Comments

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]

August 3, 2010  Tags: , , , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility

ROCKVILLE, MD, July 16, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations [...]

July 27, 2010  Tags: , , , , , ,   Posted in: Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]

July 15, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

The El-Hibri Foundation Launches Website

The El-Hibri Foundation is a nonprofit organization with the goal of fostering dialogue between various religions and encouraging nonviolent solutions to global challenges affecting humankind.  The Foundation has a new website at www.elhibrifoundation.org.
The Foundation, lead by Chairman of the Board of Trustees Fuad El-HIbri, is divided into [...]

July 14, 2010  Tags: , , , ,   Posted in: El-Hibri Peace Education Prize, Emergent BioSolutions, Foundation, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions to Participate in June 2010 Investor Conferences

Fuad El-Hibri, CEO of Emergent BioSolutions Inc., announces that the company will be participating in the following investor conferences during June 2010:

The Jefferies & Company 2010 Global Life Sciences Conference
New [...]

June 7, 2010  Tags: , , , , , ,   Posted in: Business, Emergent BioSolutions, Health Care, Healthcare Conference, fuad el-hibri  No Comments

Fuad El-Hibri and Healthcare Reform

Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University.   The 6th annual healthcare conference was held on April 9, 2010 in New Haven, CT.  The conference topic was “Re-Forming Healthcare: Excellence in a Transforming [...]

April 16, 2010  Tags: , , , , ,   Posted in: CEO, Emergent BioSolutions, Health Care, Yale University, fuad el-hibri  No Comments